HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatmentFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2022Cited by 100
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Clinical Cancer Research|2023Cited by 13
Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Clinical Cancer Research|2025Cited by 1
211P ER-low breast cancer: Evolution from primary tumor to relapse and prognostic impactFederica Miglietta, Maria Vittoria Dieci, Daniela Iannaccone et al.|ESMO Open|2023Cited by 1
Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.Federica Miglietta, Maria Vittoria Dieci, Claudio Vernieri et al.|Journal of Clinical Oncology|2024Cited by 1